Skip to content
Clinical Trials – home
FinlandBack to Finland

Clinical trials in Tampere – page 15

276 clinical trials in Tampere, Finland across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Tampere at a glance
276
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

276 trials in Tampere

Open in trial search

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of rMenB+OMV NZ meningococcal group B vaccine immune response and safety in previously vaccinated healthy participants aged 10 to 20 years

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:GlaxoSmithKline Biologicals

Study of laroprovstat (AZD0780) tablets to lower cholesterol levels in adults with inherited high cholesterol condition (heterozygous familial hypercholesterolemia)

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Study on the Effectiveness and Safety of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:534
  • Sponsor:Sanofi Pasteur Inc.

Yellow fever

Not recruiting

Study Comparing the Safety and Immune Response of the Investigational vYF Vaccine and Stamaril for Yellow Fever in Adults in Europe and Asia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Yellow fever virus strain 17D-204 (live, attenuated)
  • Sponsor:Sanofi Pasteur

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Tetanus toxoid
  • Sponsor:Sanofi Winthrop Industrie

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Diphtheria toxoid
  • Sponsor:Sanofi Pasteur Inc.

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal oligosaccharide serotype 18C conjugated to CRM197
  • Sponsor:Sanofi Pasteur Inc.
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Clesrovimab
  • Sponsor:Merck Sharp & Dohme LLC

Herpes zoster

Not recruiting

Study on Long-Term Effects and Safety of Herpes Zoster Vaccine with Recombinant Varicella Zoster Virus Glycoprotein E in Older Adults

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Immune Response of PF-07831695 and a Drug Combination for Pneumococcal Infections in Healthy Toddlers Aged 12-15 Months

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Tampere

What the registry says about research in the country

01 Infectious Disease Prevention

Extensive research focusing on vaccine development against multiple viral infections, including influenza, RSV, and meningococcal disease. Clinical trials are evaluating novel immunization strategies for different age groups.

  • Influenza vaccine trials for adults 60+
  • RSV prevention in infants and elderly
  • Meningococcal vaccines for children

Multiple studies are investigating immune responses and long-term protection against respiratory infections.

02 Oncology Research

Innovative trials exploring new treatments for various cancers, with emphasis on advanced solid tumors and blood cancers. Studies combine novel therapeutic approaches with existing treatments.

  • Breast cancer therapies
  • Leukemia treatments
  • Prostate cancer interventions

Focus on developing targeted therapies and improving treatment outcomes for cancer patients.

03 Diagnostic Medicine

Research evaluating advanced diagnostic techniques, particularly in emergency medicine and acute conditions. Studies compare different imaging methods and their effectiveness.

  • CT scanning protocols
  • Emergency diagnostics
  • Treatment response monitoring

Emphasis on improving diagnostic accuracy while considering patient safety.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.